

Research Article

Reliability and Validity of Korean Version of Crohn's and Ulcerative Colitis Questionnaire-8

Sung-Goo Kang ¹, Tae-Geun Gweon ², Han Hee Lee ², Kang-Moon Lee ²,
Sung Hoon Jung ² and Sang-Bum Kang ²

¹Department of Family Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea

²Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Republic of Korea

Correspondence should be addressed to Sung Hoon Jung; shjung74@catholic.ac.kr and Sang-Bum Kang; dxandtx@catholic.ac.kr

Received 3 June 2022; Revised 2 September 2022; Accepted 24 September 2022; Published 7 October 2022

Academic Editor: Luisa Brussino

Copyright © 2022 Sung-Goo Kang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Patients with inflammatory bowel disease (IBD) have a decreased quality of life (QoL), the improvement of which is a treatment goal. The CUCQ-8 is a verified simple and effective QoL measurement tool. We validated the Korean version of CUCQ-8 with the approval of its developer. **Methods.** We investigated the correlation between the Korean version of CUCQ-8 and the IBDQ-32 in patients with IBD. **Results.** In all, 147 subjects (male, 97 (66.0%); female, 50 (34.0%); mean age 36.2 ± 13.5 years) were analyzed. Cronbach's alpha coefficient of the CUCQ-8 was 0.833, indicating very high internal consistency. The Korean version of the CUCQ-8 showed a significant correlation with the IBDQ-32 and its subscales (correlation coefficient, >0.75). **Conclusions.** The Korean version of the CUCQ-8 has high reliability and construct validity and can be used to evaluate the QoL of patients with IBD.

1. Introduction

Inflammatory bowel diseases (IBDs), such as Crohn's disease (CD) and ulcerative colitis (UC), are idiopathic chronic inflammatory diseases of the gastrointestinal tract [1–3]. Globally, the number of patients with IBD continues to increase, mainly in developing countries, and the incidence and prevalence of IBD are steadily increasing in South Korea [4]. The main symptoms of IBD are abdominal pain, diarrhea, bloody stool, and urgency, and extraintestinal symptoms in the joints and skin. IBD is incurable, recurs repeatedly, and requires hospitalization in some cases. In addition, the physical symptoms of IBD can cause chronic fatigue and depression, which are related to a decrease in the quality of life (QoL) [5–8].

Demographic characteristics, disease-related factors, and psychosocial factors are related to the QoL of patients with IBD. A decreased QoL is related to disease activity, Crohn's disease, female sex, older age, and IBD surgery [9].

QoL measures provide insight into patients' perceptions of their health and how it is affected by the treatments they receive. Therefore, it is important to measure the QoL of patients with IBD, for which a simple and reliable tool is required.

The Inflammatory Bowel Disease Questionnaire (IBDQ) is used for research on the QoL of patients with IBD. In South Korea, a study evaluated the QoL of patients with Crohn's disease, ulcerative colitis, and Behcet's disease using the IBDQ [10]. However, the IBDQ is complicated and inconvenient to use in clinical practice because of the large number of questions and high level of complexity. The Crohn's and Ulcerative Colitis Questionnaire-8 (CUCQ-8) is a verified, simple, and effective QoL measurement tool [11]. To date, the CUCQ-8 has not been approved by its developer for use in South Korea. With the approval of the developer, we evaluated the reliability, validity, and utility of the Korean version of the CUCQ-8 for measuring the QoL of patients with IBD in South Korea.

2. Materials and Methods

2.1. Study Population. This was a multicenter study involving five institutions of the Catholic University of Korea (Daejeon St. Mary's, Eunpyeong St. Mary's, Yeouido St. Mary's, Bucheon St. Mary's, and St. Vincent's Hospitals) and including 147 patients diagnosed with Crohn's disease or ulcerative colitis. Consecutive patients with confirmed diagnoses of CD and UC were enrolled prospectively. We excluded patients who were under 18, non-Korean speakers, and with severe mental illness. Disease activity was measured using the Crohn's Disease Activity Index (CDAI) [12] and Mayo score [13].

The researchers explained the purpose of the study and the composition, contents, and precautions of the questionnaire to the subjects. The subjects were given sufficient time to read and respond to the questions. Subjects completed the questionnaire and asked the researchers to clarify any ambiguity. The subjects' age, sex, body mass index (BMI), disease duration, and history of IBD surgery were investigated.

2.2. IBDQ. The IBDQ, developed by Guyatt et al. [14], is used to evaluate the QoL of patients with IBD. The IBDQ consists of 32 items and has four subscales. There are 10 items on bowel symptoms, 5 on systemic symptoms, 5 on social functions, and 12 on emotional functions. Each item is rated on a 7-point Likert scale, with 1 indicating the most severe problem and 7 indicating no problem at all. We received permission from the McMaster Industry Liaison Office, which holds the copyright for the IBDQ, to use the Korean version of the IBDQ. The total IBDQ score is 32 to 224 points, and a higher score reflects a higher QoL.

2.3. CUCQ-8 Scoring. The CUCQ-8 questionnaire evaluates intestinal problems in the prior 2 weeks and their effects on QoL. It assesses loose or runny bowel movement, bloody stool, tiredness, frustration, urgency or awakening at night to use the toilet, and social inhibition. The total score is 0 to 24, and the higher the score, the lower the QoL.

2.4. Translation of the CUCQ-8. The CUCQ-8 items were translated with the approval of the developer, Laith Al-Rubaiy, and according to the recommendations of Guillemin et al. [15] and Beaton et al. [15, 16] First, two people (one the corresponding author) fluent in both English and Korean with Korean as their mother tongue translated the items from English to Korean. One translator was blinded to the purpose of the study to improve the quality of the translation. Next, four specialists discussed and analyzed the differences between the two translations and generated a complete translation. Subsequently, two new translators (who were not involved in biomedical science and unaware of the purpose of the study) back-translated the items into English. Finally, four specialists discussed and analyzed the reverse translation to produce the final Korean version of the CUCQ-8.

2.5. Statistical Analysis. The Statistical Package for the Social Sciences (SPSS) version 18.0 for Windows was used for statistical analysis. The CUCQ-8 items were assessed for inter-

nal consistency using Cronbach's alpha reliability coefficient [17]. The convergent validity of the total CUCQ-8 score was tested using Pearson's correlation coefficient with the IBDQ score. Chi-square and *t*-tests were performed to examine differences in variables between the IBD groups, and multiple linear regression tests were conducted to identify factors affecting the CUCQ-8 score. Exploratory factor analysis was performed to assess the structure of the CUCQ-8 questionnaire. Factors with eigenvalues of >1 were identified by principal component analysis. A value of $P < 0.05$ was taken to indicate statistical significance.

2.6. Ethical Considerations. This study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review boards of the participating hospitals (XC19QEDI0052). Written informed consent was obtained from the subjects. Subjects were instructed to respond to all questionnaire items after reading the instructions.

3. Results

3.1. Demographics and Clinical Characteristics. In all, 147 subjects of mean age 36.2 ± 13.5 years were included. All enrolled patients were Asian. Among them, 50 (34.0%) were female and 97 (66.0%) were male. Although the UC group was significantly older than the CD group, there were no significant differences in sex ratio, BMI, or disease duration. There were no significant differences in the CUCQ-8 total score or IBDQ total score between the UC and CD groups (Table 1). The CUCQ total score according to demographic characteristics did not differ significantly between the UC and CD groups (Table 2).

3.2. Internal Consistency and Structural Validity. Cronbach's alpha coefficient of CUCQ-8 was 0.833, indicating very high internal consistency. To investigate the structure validity of the CUCQ-8, principal component analysis was performed after varimax rotation. Two factors with eigenvalues of >1.0 explained 63.0% of the variables. Factor 1 (eigenvalue 3.9) explained 35.7% of the variables, including five CUCQ-8 items. The factor loading of all-but-one item exceeded 0.60. Factor 2 (eigenvalue 1.1) explained 27.3% of the variables, including three CUCQ-8 items. The factor loading of all-but-one item of factor 2 exceeded 0.60.

3.3. Construct Validity. The CUCQ-8 had good construct validity. The Korean CUCQ-8 total score showed a significant correlation with the IBDQ total score and its subscales. The correlation coefficient for the relationships between the four subtypes of the IBDQ and the CUCQ-8 total score was very high at ≥ 0.75 , showing statistical significance (Table 3 and Figure 1). The Mayo and CDAI scores were significantly positively correlated with the CUCQ-8 total score.

3.4. Factors Affecting the CUCQ-8 Total Score. Multiple linear regressions showed that age, sex, BMI, and disease duration did not affect the CUCQ-8 total score in patients with UC or CD. Disease activity (Mayo score for UC and CDAI for CD) had a statistically significant effect on the CUCQ-8 total score (Tables 4 and 5).

TABLE 1: Baseline characteristics of the study population.

	IBD total (<i>n</i> = 147)	UC (<i>n</i> = 97)	CD (<i>n</i> = 50)	<i>P</i> value
Age (years)	36.2 ± 13.5	40.3 ± 13.8	28.3 ± 8.70	<0.001
Sex				0.070
Male	97 (66.0)	59 (60.8)	38 (76.0)	
Female	50 (34.0)	38 (39.2)	12 (24.0)	
BMI (kg/m ²)	22.6 ± 3.7	22.7 ± 3.3	22.3 ± 3.5	0.594
Duration of disease (years)	4.6 ± 5.9	4.6 ± 5.9	4.7 ± 6.0	0.921
≤1year	42 (28.6)	25 (25.8)	17 (34.0)	
1-5 years	59 (40.1)	42 (43.3)	17 (34.0)	
≥5 years	46 (31.3)	30 (30.9)	16 (32.0)	
History of operation for IBD	11 (7.5)	0 (0)	11 (22)	<0.001
CUCQ-8 total score	9.7 ± 5.9	9.3 ± 6.0	10.4 ± 5.8	0.297
IBDQ total score	161.2 ± 39.9	162.7 ± 40.5	158.2 ± 39.0	0.521
IBDQ-BS	52.0 ± 13.3	52.0 ± 13.8	51.9 ± 12.4	0.959
IBDQ-SS	23.2 ± 6.7	23.8 ± 6.5	21.9 ± 7.0	0.096
IBDQ-EF	58.5 ± 15.6	59.3 ± 15.4	56.8 ± 16.1	0.344
IBDQ-SF	27.6 ± 7.5	27.5 ± 7.9	27.7 ± 6.6	0.900

Data are mean ± SD or *N* (%). *P* values were obtained by independent *t*-tests or chi-square tests. Abbreviations: BMI: body mass index; CUCQ-8: Crohn's and Ulcerative Colitis Questionnaire-8; IBDQ: Inflammatory Bowel Disease Questionnaire; BS: bowel symptoms; SS: social symptoms; EF: emotional function; SF: social function.

TABLE 2: CUCQ-8 total score according to demographic characteristics.

	IBD total (<i>n</i> = 147)	UC (<i>n</i> = 97)	CD (<i>n</i> = 50)	<i>P</i> value
Age (years)				
<40	9.5 ± 5.9	9.1 ± 6.1	10.0 ± 5.8	0.493
≥40	10.1 ± 6.0	9.6 ± 6.0	13.0 ± 5.6	0.169
Sex				
Male	9.6 ± 6.2	9.3 ± 6.4	10.0 ± 5.9	0.626
Female	9.9 ± 5.4	9.2 ± 5.3	11.8 ± 5.5	0.168
BMI (kg/m ²)				
<25	9.9 ± 6.1	9.7 ± 6.1	10.4 ± 6.0	0.570
≥25	8.0 ± 4.9	7.2 ± 5.3	9.4 ± 4.1	0.273
Duration of disease (years)				
<1year	11.1 ± 6.0	11.0 ± 6.4	11.2 ± 5.6	0.945
1-5 years	8.8 ± 6.2	8.6 ± 6.4	9.3 ± 6.0	0.736
>5 years	9.4 ± 5.3	8.7 ± 4.8	10.6 ± 5.9	0.256
History of operation for IBD				
No	9.6 ± 5.9	9.3 ± 6.0	10.2 ± 5.8	0.411
Yes	11.0 ± 5.8	—	11.0 ± 5.8	—

Data are mean ± SD or *N* (%). *P* values were obtained by independent *t*-tests or chi-square tests. Abbreviations: BMI: body mass index; CUCQ-8: Crohn's and Ulcerative Colitis Questionnaire-8.

4. Discussion

QoL measures provide insight into patients' perceptions of their health and how it is affected by the treatments they receive. Therefore, it is important to measure the QoL of patients with IBD. CUCQ-32 and IBDQ-32 have been used

to measure quality of life in IBD [10, 11, 17]. However, these tools are very complex and time-consuming. CUCQ-8 was recently validated as a reliable and suitable short questionnaire for monitoring QOL in IBD patients similar to CUCQ-32. While IBDQ-32 should be used for a fee, CUCQ-8 is available free for healthcare providers to support

TABLE 3: Correlation between CUCQ-8 total score and IBDQ total and subscales score in UC and CD.

	IBD total		UC		CD	
	<i>r</i>	<i>P</i> value	<i>r</i>	<i>P</i> value	<i>r</i>	<i>P</i> value
IBDQ total score	-0.884	<0.001	-0.889	<0.001	-0.874	<0.001
IBDQ-BS	-0.848	<0.001	-0.857	<0.001	-0.837	<0.001
IBDQ-SS	-0.829	<0.001	-0.845	<0.001	-0.796	<0.001
IBDQ-EF	-0.821	<0.001	-0.828	<0.001	-0.805	<0.001
IBDQ-SF	-0.763	<0.001	-0.760	<0.001	-0.784	<0.001
Mayo score			0.438	<0.001		
CDAI					0.425	0.003

P value was calculated by Pearson's correlation. Abbreviations: CUCQ-8: Crohn's and Ulcerative Colitis Questionnaire-8; IBDQ: Inflammatory Bowel Disease Questionnaire; BS: bowel symptoms; SS: social symptoms; EF: emotional function; SF: social function; CDAI: Crohn's Disease Activity Index.




FIGURE 1: Correlation between CUCQ-8 total score and IBDQ total score.

TABLE 4: Multiple linear regression between CUCQ-8 total score and other cofactors in UC patients.

	β	<i>P</i> value
Age (years)	0.030	0.484
Sex (female)	0.129	0.920
BMI (kg/m ²)	-0.291	0.135
Disease duration (years)	-0.111	0.277
Mayo score	0.847	<0.001

Abbreviations: BMI: body mass index; CUCQ-8: Crohn's and Ulcerative Colitis Questionnaire-8.

patient care without licensing fees in clinical practice to assess QoL. Therefore, we evaluated the reliability and validity of the Korean version of the CUCQ-8, a measure of the QoL of patients with IBD.

Cronbach's alpha value of >0.7 is considered reliable [15]. In the first study of the CUCQ-8 [11], Cronbach's alpha coefficient was 0.84 in patients with mild to moderate IBD. Hutchings et al. [18] reported that in patients with severe UC, the CUCQ-8 had Cronbach's alpha coefficient of 0.845, indicating excellent internal consistency. In this study, Cronbach's alpha coefficient of the Korean version of the CUCQ-8 was also very good at 0.833.

TABLE 5: Multiple linear regression between CUCQ-8 total score and other cofactors in CD patients.

	β	<i>P</i> value
Age (years)	-0.046	0.760
Sex (female)	2.415	0.213
BMI (kg/m ²)	0.055	0.767
Disease duration (years)	0.148	0.508
History of operation for IBD	1.289	0.583
CDAI	2.756	0.003

Abbreviations: BMI: body mass index; CUCQ-8: Crohn's and Ulcerative Colitis Questionnaire-8; CDAI: Crohn's Disease Activity Index.

Principal component analysis detected two major factors with eigenvalues of >1, explaining 63.0% of the total variance in the CUCQ-8. The first factor explained 35.7% of the total variance, and the eigenvalue was 3.96. The items included in the first factor were "1. On how many days over the last 2 weeks have you felt tired?", "2. In the last 2 weeks did your bowel condition prevent you from going out socially?", "3. On how many days over the last 2 weeks have you felt generally unwell?", "4. On how many days over the last 2 weeks have you felt pain in your abdomen?", and "6.

On how many days over the last 2 weeks has your abdomen felt bloated?”. The first factor consisted of five items, including abdominal pain or discomfort symptoms and related fatigue and an unhealthy feeling. The second factor explained 27.3% of the total variance, and the eigenvalue was 1.1. The items included in this factor were “5. On how many nights in the last 2 weeks have you had to get up to use the toilet because of your bowel condition after you have gone to bed?”, “7. In the last 2 weeks have you felt upset?”, and “8. On how many days over the last 2 weeks have you had to rush to the toilet?”. The second factor consisted of a total of three items including urge to defecate and mainly consisted of items such as emotion related to this symptom.

The total score on the Korean CUCQ-8 had very good construct validity and was significantly correlated with the IBDQ total score. The CUCQ-8 total score had correlation coefficients of ≥ 0.75 with not only the IBDQ total score but also its four subscales.

This study had several limitations. First, there were fewer patients with CD than with UC. However, compared to previous similar studies ($n = 150 - 200$), the total number of subjects was not small [10, 11]. Second, few of the subjects had severe IBD. In the future, additional studies on acute severe patients are needed. Finally, educational background, economic background, and marital status, which affect QoL, were not investigated.

However, despite these limitations, our findings show that the Korean version of the CUCQ-8 is suitable for measuring the QoL of patients with IBD. The IBDQ has 32 questions and takes a long time to complete and for the total score to be calculated. In comparison, the Korean version of the CUCQ-8 has just eight questions and takes 1–2 min to complete. In addition, because each item can be converted into a 4-point Likert scale, the total score can be calculated relatively quickly. In addition, as mentioned above, the Pearson correlation coefficient of the CUCQ-8 total score and IBDQ total score in this study was 0.884. Given that the Pearson correlation coefficient of the CUCQ-8 and CUCQ-32 total score was originally reported to be 0.91 [11], the CUCQ-8 has very good construct validity. These data demonstrate the utility of the Korean version of CUCQ-8 for measuring the QoL of patients with IBD.

A follow-up study is needed to determine whether the QoL is improved when disease activity is reduced. In addition, the Korean version of the CUCQ-8 will be useful for evaluating the efficacy of novel biologic therapeutics for IBD.

Data Availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval

This study was approved by the Institutional Review Board of the Catholic University of Korea (XC19QEDI0052).

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Authors' Contributions

S.B.K and S.H.J. planned and designed the review. T.G.G, H.H.L, K.M.L, S.B.K, and S.H.J carried out data collection. S.G.K drafted the manuscript and performed data analysis. S.B.K and S.H.J. supervised the writing of the manuscript. All authors reviewed and approved the final draft of the manuscript. Sung Hoon Jung and Sang-Bum Kang contributed equally to this work.

Supplementary Materials

English Certificate.pdf. (*Supplementary Materials*)

References

- [1] A. Ponder and M. D. Long, “A clinical review of recent findings in the epidemiology of inflammatory bowel disease,” *Clinical Epidemiology*, vol. 5, pp. 237–247, 2013.
- [2] S. C. Ng, C. N. Bernstein, M. H. Vatn et al., “Geographical variability and environmental risk factors in inflammatory bowel disease,” *Gut*, vol. 62, no. 4, pp. 630–649, 2013.
- [3] J. Cosnes, C. Gower-Rousseau, P. Seksik, and A. Cortot, “Epidemiology and natural history of inflammatory bowel diseases,” *Gastroenterology*, vol. 140, no. 6, pp. 1785–1794.e4, 2011.
- [4] S. H. Park, Y. J. Kim, K. H. Rhee et al., “A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong District of Seoul, Korea in 1986–2015,” *Journal of Crohn's & Colitis*, vol. 13, no. 11, pp. 1410–1417, 2019.
- [5] D. R. van Langenberg and P. R. Gibson, “Systematic review: fatigue in inflammatory bowel disease,” *Alimentary Pharmacology & Therapeutics*, vol. 32, no. 2, pp. 131–143, 2010.
- [6] A. Mitchell, G. Guyatt, J. Singer et al., “Quality of life in patients with inflammatory bowel disease,” *Journal of Clinical Gastroenterology*, vol. 10, no. 3, pp. 306–310, 1988.
- [7] L. P. Jelsness-Jørgensen, T. Bernklev, M. Henriksen, R. Torp, and B. A. Moum, “Chronic fatigue is more prevalent in patients with inflammatory bowel disease than in healthy controls,” *Inflammatory Bowel Diseases*, vol. 17, no. 7, pp. 1564–1572, 2011.
- [8] L. P. Jelsness-Jørgensen, T. Bernklev, M. Henriksen, R. Torp, and B. A. Moum, “Chronic fatigue is associated with impaired health-related quality of life in inflammatory bowel disease,” *Alimentary Pharmacology & Therapeutics*, vol. 33, no. 1, pp. 106–114, 2011.
- [9] G. Huppertz-Hauss, M. Lie Høivik, L. P. Jelsness-Jørgensen et al., “Health-related quality of life in patients with inflammatory bowel disease 20 years after diagnosis: results from the IBSEN study,” *Inflammatory Bowel Diseases*, vol. 22, no. 7, pp. 1679–1687, 2016.
- [10] W. H. Kim, Y. S. Cho, H. M. Yoo, I. S. Park, E. C. Park, and J. G. Lim, “Quality of life in Korean patients with inflammatory bowel diseases: ulcerative colitis, Crohn's disease and

- intestinal Behçet's disease," *International Journal of Colorectal Disease*, vol. 14, no. 1, pp. 52–57, 1999.
- [11] L. Alrubaiy, W. Y. Cheung, P. Dodds et al., "Development of a short questionnaire to assess the quality of life in Crohn's disease and ulcerative colitis," *Journal of Crohn's & Colitis*, vol. 9, no. 1, pp. 66–76, 2015.
- [12] W. R. Best, J. M. Beckett, J. W. Singleton, and F. Kern Jr., "Development of a Crohn's disease activity index: national cooperative Crohn's disease study," *Gastroenterology*, vol. 70, no. 3, pp. 439–444, 1976.
- [13] G. D'Haens, W. J. Sandborn, B. G. Feagan et al., "A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis," *Gastroenterology*, vol. 132, no. 2, pp. 763–786, 2007.
- [14] G. Guyatt, A. Mitchell, E. J. Irvine et al., "A new measure of health status for clinical trials in inflammatory bowel disease," *Gastroenterology*, vol. 96, no. 2, pp. 804–810, 1989.
- [15] F. Guillemin, C. Bombardier, and D. Beaton, "Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines," *Journal of Clinical Epidemiology*, vol. 46, no. 12, pp. 1417–1432, 1993.
- [16] D. E. Beaton, C. Bombardier, F. Guillemin, and M. B. Ferraz, "Guidelines for the process of cross-cultural adaptation of self-report measures," *Spine*, vol. 25, no. 24, pp. 3186–3191, 2000.
- [17] L. Alrubaiy, R. Sikafi, H. A. Hutchings, I. Arnott, and J. G. Williams, "Further validation of the Crohn's and ulcerative colitis questionnaire-32 (CUCQ-32) to measure the quality of life in patients treated with biologics therapy," *Clinical Practice*, vol. 12, no. 3, pp. 436–448, 2022.
- [18] H. A. Hutchings, L. Alrubaiy, A. Watkins, W. Y. Cheung, A. C. Seagrove, and J. G. Williams, "Validation of the Crohn's and ulcerative colitis questionnaire in patients with acute severe ulcerative colitis," *United European Gastroenterology Journal*, vol. 5, no. 4, pp. 571–578, 2017.